SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001689813-22-000049
Filing Date
2022-05-11
Accepted
2022-05-10 21:42:35
Documents
16
Period of Report
2022-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220509.htm   iXBRL 8-K 62963
2 EX-2.1 ex21agreementandplanofmerg.htm EX-2.1 951782
3 EX-2.2 ex22separationanddistribut.htm EX-2.2 664623
7 GRAPHIC screenshot2022-05x10at4564a.jpg GRAPHIC 25459
8 GRAPHIC untitleda.jpg GRAPHIC 16478
  Complete submission text file 0001689813-22-000049.txt   2122165

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220509.xsd EX-101.SCH 1920
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220509_lab.xml EX-101.LAB 23800
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220509_pre.xml EX-101.PRE 12508
10 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220509_htm.xml XML 10538
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 22911874
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences